Heart Failure Beat Podcast: MRAs in HFpEF & HFmrEF: A Clinical Debate - Episode 45
Description:
Are mineralocorticoid receptor antagonists (MRAs) ready for prime time in HFpEF and HFmrEF?
In this special debate-format episode of the Heart Failure Beat, two leading heart failure pharmacists, Stormi Gale, PharmD, BCCP, FHFSA and Robert L Page II, PharmD, MSPH, FHFSA, go head-to-head on steroidal vs non-steroidal MRAs.
From RALES and TOPCAT to FINEARTS-HF, they unpack the evidence, guideline implications, cost-effectiveness, CKM considerations, and real-world barriers to access. Is finerenone the “new pillar” in HFpEF? Or does spironolactone remain the practical, evidence-based choice? The conversation also explores phenotyping challenges in HF trials and whether combining SGLT2 inhibitors with MRAs can attenuate hyperkalemia risk.
If you care about precision medicine, cardiorenal overlap, or optimizing GDMT in complex patients, this debate is for you.
Tune into highlight clips on YouTube
HFSA Heart Failure Beat: Phenotyping in Heart Failure Trials
HFSA Heart Failure Beat: SGLT2 Inhibitors & MRAs: Attenuating Hyperkalemia Risk
Guest names and titles:
Hosts: Michael Beasley, MD and Priya Umapathi, MD
Guests: Stormi Gale, PharmD, BCCP, FHFSA and Robert L Page II, PharmD, MSPH, FHFSAURL to episode webpage: https://hfsa.org/heart-failure-beat-mras-hfpef-hfmref-clinical-debate